Sex differences in clinical presentation and response in panic disorder: pooled data from sertraline treatment studies
- PMID:16292466
- DOI: 10.1007/s00737-005-0111-y
Sex differences in clinical presentation and response in panic disorder: pooled data from sertraline treatment studies
Abstract
Objective: Gender differences in clinical presentation and response to sertraline treatment were examined for patients diagnosed with DSM-III-R panic disorder with or without agoraphobia.
Method: Data was pooled from 4 double-blind, placebo-controlled outpatient studies (males, N = 335; females, N = 338). Two were 12-week fixed-dose studies (sertraline 50 mg vs. 100 mg vs. 200 mg) and 2 were 10-week flexible-dose studies (sertraline 50-200 mg). Primary outcome measures consisted of the Clinical Global Impression-Improvement scale (CGI-I) and change in panic attack frequency.
Results: The clinical presentation of panic disorder was similar except that men reported an earlier age of onset, shorter duration of illness, and significantly more frequent history of alcohol and/or substance dependence/abuse. Sertraline was significantly more effective than placebo in both women and men on the 2 primary outcome measures. When between-sex efficacy was compared, women achieved significantly greater improvement than men on panic frequency and CGI-I, but had equivalent improvement on all other measures. There was no significant between-sex difference in study completion rates, or in adverse event profiles.
Conclusions: There was a modest but consistent trend for women to show superior efficacy at the end of acute sertraline treatment. This gender effect only occasionally achieved significance, and must be confirmed by future treatment research.
Similar articles
- Sertraline treatment of panic disorder: response in patients at risk for poor outcome.Pollack MH, Rapaport MH, Clary CM, Mardekian J, Wolkow R.Pollack MH, et al.J Clin Psychiatry. 2000 Dec;61(12):922-7.J Clin Psychiatry. 2000.PMID:11206597
- Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder.Pollack MH, Rapaport MH, Fayyad R, Otto MW, Nierenberg AA, Clary CM.Pollack MH, et al.J Psychiatr Res. 2002 Jul-Aug;36(4):229-36. doi: 10.1016/s0022-3956(02)00010-9.J Psychiatr Res. 2002.PMID:12191627
- Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R.Pollack MH, et al.Arch Gen Psychiatry. 1998 Nov;55(11):1010-6. doi: 10.1001/archpsyc.55.11.1010.Arch Gen Psychiatry. 1998.PMID:9819070Clinical Trial.
- Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia.Bakker A, van Balkom AJ, van Dyck R.Bakker A, et al.Int Clin Psychopharmacol. 2000 Aug;15 Suppl 2:S25-30. doi: 10.1097/00004850-200008002-00005.Int Clin Psychopharmacol. 2000.PMID:11110016Review.
- Sertraline in the treatment of panic disorder.Hobgood CD, Clayton AH.Hobgood CD, et al.Drugs Today (Barc). 2009 May;45(5):351-61. doi: 10.1358/dot.2009.45.5.1362066.Drugs Today (Barc). 2009.PMID:19584964Review.
Cited by
- Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness.McLean CP, Asnaani A, Litz BT, Hofmann SG.McLean CP, et al.J Psychiatr Res. 2011 Aug;45(8):1027-35. doi: 10.1016/j.jpsychires.2011.03.006. Epub 2011 Mar 25.J Psychiatr Res. 2011.PMID:21439576Free PMC article.
- Sex differences in anxiety and emotional behavior.Donner NC, Lowry CA.Donner NC, et al.Pflugers Arch. 2013 May;465(5):601-26. doi: 10.1007/s00424-013-1271-7. Epub 2013 Apr 16.Pflugers Arch. 2013.PMID:23588380Free PMC article.Review.
- Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review.Gartlehner G, Chapman A, Strobelberger M, Thaler K.Gartlehner G, et al.PLoS One. 2010 Jul 30;5(7):e11895. doi: 10.1371/journal.pone.0011895.PLoS One. 2010.PMID:20689584Free PMC article.
- Panic attacks and panic disorder in the American Indian community.Sawchuk CN, Roy-Byrne P, Noonan C, Craner JR, Goldberg J, Manson S, Buchwald D; AI-SUPERPFP Team.Sawchuk CN, et al.J Anxiety Disord. 2017 May;48:6-12. doi: 10.1016/j.janxdis.2016.10.004. Epub 2016 Oct 5.J Anxiety Disord. 2017.PMID:27720578Free PMC article.
- Associations between prefrontal γ-aminobutyric acid concentration and the tryptophan hydroxylase isoform 2 gene, a panic disorder risk allele in women.Preuss N, Salehi B, van der Veen JW, Shen J, Drevets WC, Hodgkinson C, Goldman D, Hasler G.Preuss N, et al.Int J Neuropsychopharmacol. 2013 Sep;16(8):1707-17. doi: 10.1017/S1461145713000254. Epub 2013 Apr 3.Int J Neuropsychopharmacol. 2013.PMID:23552096Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical